Armistice Capital, LLC's Form 4 filing
Avalo Therapeutics, Inc. (AVTX) · filed Aug 18, 2021
- Accession no.
- 0000899243-21-033505
- Filed
- Aug 18, 2021, 5:54 PM ET
- Trade date
- Aug 16-18, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $138.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Armistice Capital, LLCCIK 0001601086 | Director, 10% Owner |
| Armistice Capital Master Fund Ltd.CIK 0001633584 | Director, 10% Owner |
| Boyd StevenCIK 0001706140 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2021 | Common Stock | PPurchaseAcquired | +30,000 | $2.75F2 | +$82,638 | 39,280,000 | Indirect | |
| Aug 18, 2021 | Common Stock | PPurchaseAcquired | +20,000 | $2.78 | +$55,550 | 39,300,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.7507 to $2.774, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Each of the Master Fund and Armistice Capital may be deemed a director by deputization of the Issuer by virtue of the fact that Steven Boyd, a representative of the Master Fund and Armistice Capital, currently serves on the Issuer's board of directors.